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AbsTRACT
The therapeutic management of Sjögren syndrome 
(SjS) has not changed substantially in recent decades: 
treatment decisions remain challenging in clinical 
practice, without a specific therapeutic target beyond the 
relief of symptoms as the most important goal. In view of 
this scenario, the European League Against Rheumatism 
(EULAR) promoted and supported an international 
collaborative study (EULAR SS Task Force) aimed at 
developing the first EULAR evidence and consensus- 
based recommendations for the management of patients 
with SjS with topical and systemic medications. The aim 
was to develop a rational therapeutic approach to SjS 
patients useful for healthcare professionals, physicians 
undergoing specialist training, medical students, 
the pharmaceutical industry and drug regulatory 
organisations following the 2014 EULAR standardised 
operating procedures. The Task Force (TF) included 
specialists in rheumatology, internal medicine, oral 
health, ophthalmology, gynaecology, dermatology and 
epidemiology, statisticians, general practitioners, nurses 
and patient representatives from 30 countries of the 5 
continents. Evidence was collected from studies including 
primary SjS patients fulfilling the 2002/2016 criteria; 
when no evidence was available, evidence from studies 
including associated SjS or patients fulfilling previous 
sets of criteria was considered and extrapolated. The TF 
endorsed the presentation of general principles for the 
management of patients with SjS as three overarching, 
general consensus- based recommendations and 12 
specific recommendations that form a logical sequence, 
starting with the management of the central triplet of 
symptoms (dryness, fatigue and pain) followed by the 
management of systemic disease. The recommendations 
address the use of topical oral (saliva substitutes) and 
ocular (artificial tear drops, topical non- steroidal anti- 
inflammatory drugs, topical corticosteroids, topical 
CyA, serum tear drops) therapies, oral muscarinic 
agonists (pilocarpine, cevimeline), hydroxychloroquine, 
oral glucocorticoids, synthetic immunosuppressive 
agents (cyclophosphamide, azathioprine, methotrexate, 
leflunomide and mycophenolate), and biological 
therapies (rituximab, abatacept and belimumab). For 
each recommendation, levels of evidence (mostly 
modest) and TF agreement (mostly very high) are 
provided. The 2019 EULAR recommendations are 
based on the evidence collected in the last 16 years in 
the management of primary 2002 SjS patients and on 
discussions between a large and broadly international 
TF. The recommendations synthesise current thinking 
on SjS treatment in a set of overarching principles 
and recommendations. We hope that the current 
recommendations will be broadly applied in clinical 
practice and/or serve as a template for national societies 
to develop local recommendations.
InTRoduCTIon
Sjögren syndrome (SjS), a systemic autoimmune 
disease that affects 1–23 persons per 10 000 inhab-
itants in European countries,1 presents with a 
wide spectrum of clinical manifestations and auto-
antibodies. Antinuclear antibodies are the most 
frequently detected autoantibodies, anti- Ro/SS- A the 
most specific, and cryoglobulins and hypocomple-
mentaemia the main prognostic markers.2 The histo-
logical hallmark is a focal infiltration of the exocrine 
glands by lymphocytes, determined by minor labial 
salivary gland biopsy. The clinical scenario is domi-
nated by sicca syndrome caused by immune- mediated 
glandular involvement, accompanied by fatigue, 
musculoskeletal pain and systemic features in a signif-
icant percentage of patients, and complicated by 
lymphoma in around 2%–5% of patients.3 When SjS 
appears in a previously healthy person, the disease is 
classified as primary, while patients with concomitant 
systemic autoimmune diseases (SAD) are classified as 
associated (or secondary) SjS; since this distinction 
only reflects a clinical situation of autoimmune coex-
istence the term SjS will be throughout the manu-
script. SjS patients make substantial use of healthcare 
services, with a mean annual total direct cost per 
patient ranging between £2200 in UK and US$20 000 
in the USA.4 5
The therapeutic management of SjS has not 
changed substantially in recent decades6 and is 
still based on symptomatic treatment of sicca 
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symptomatology and broad- spectrum immunosuppression for 
systemic disease, with insufficient information on the differential 
efficacy and safety of the therapeutic options available.7 Treat-
ment decisions remain challenging in clinical practice, without a 
specific therapeutic target beyond the relief of symptoms as the 
most important goal. Therefore there is growing interest in the 
proposal of clinical guidelines by national scientific societies.8–11
In 2010, the European League Against Rheumatism (EULAR) 
promoted and supported an international collaborative study 
(EULAR SS Task Force) aimed at developing disease- specific 
activity indexes in SjS (EULAR Sjögren's Syndrome Patient 
Reported Index (ESSPRI) and EULAR Sjögren's syndrome 
disease activity index (ESSDAI) scores),12 13 which are now 
widely used both clinically and in research. A second project, the 
development of the first EULAR evidence and consensus- based 
recommendations for the management of patients with SjS with 
topical and systemic medications, was proposed and launched.
MeTHods
After approval of the proposal by the EULAR Executive 
Committee, the convenor (MR- C) and co- convenors (CV, SB, 
XM) invited international experts with a solid history of clinical 
research in SjS (most of whom were previously involved in the 
ESSDAI/ESSPRI project) to form part of a Steering Committee 
(SC) and a Task Force (TF), which also included methodologists, 
patient representatives and individuals from all relevant profes-
sional groups (online supplementary appendix 1). The aim was 
to develop a rational therapeutic approach to SjS patients that 
would be useful for healthcare professionals, doctors in specialist 
training, medical students, the pharmaceutical industry and 
drug regulatory organisations following the 2014 EULAR stan-
dardised operating procedures.14 Industry involvement was not 
permitted at any stage of the project.
steering committee
The SC included 13 rheumatologists, four internal medicine, one 
primary care and one oral health specialists, one epidemiologist, 
one statistician, one healthcare professional representative and 
two patient representatives. The SC agreed on some principal 
considerations upfront: (a) The statements were termed ‘recom-
mendations’ as opposed to ‘guidelines’ or ‘points to consider’ 
because they offer guidance, which needs to be tailored to meet 
individual requirements. (b) Some general rules and definitions 
(overarching principles, general recommendations, defini-
tion of sequential therapeutic schedules, severity or refractori-
ness) cannot be evidence- based and were, therefore based on 
consensus. (c) The remaining statements were evidence- based, 
that is, supported by the highest level of evidence possible, 
limiting statements based only on retrospective data (although 
for some clinical or therapeutic scenarios with no data in 
controlled studies, this was allowed if the amount of retrospec-
tive data was considered significant and scientifically reliable); 
recommendations based on data obtained from case reports 
were not allowed. (d) Evidence was collected from studies 
including primary SjS patients fulfilling the 2002/2016 criteria 
(SjS-2002).15 16 When no evidence was available, evidence from 
studies including associated SjS, patients fulfilling previous sets 
of criteria or those including a mix of autoimmune and non- 
autoimmune aetiologies was considered and extrapolated (online 
supplementary table S1). (e) The balance between efficacy and 
side effects was evaluated agent by agent. (f) Although recom-
mendations are primarily supported by the evidence reported 
in patients with primary SjS, the advice on topical and systemic 
management contained in these guidelines may be applicable to 
patients with associated (or secondary) SjS.
systematic literature review
A previous systematic literature review (SLR) reported by the 
convenor in 20107 served to provide SC members with a back-
ground to initiate discussions and propose research questions 
for the SLR focused on the therapeutic management of SjS. 
On the basis of the research questions, PBZ and SR carried out 
the SLR between January 1986 and December 2017, with the 
supervision of the convenor and the methodologists. Summary- 
of- findings (SoF) tables were generated and levels of evidence 
(LoE) were determined according to the study design, using the 
Oxford CEBM standards17 (online supplementary table S1). 
The SoFs of the SLR were presented to the SC, whose members 
formulated a first draft of recommendations based on this infor-
mation, using electronic and cloud- based working strategies to 
review the literature search, making comments and maintaining 
open communication for electronic discussion and amendments. 
The SLR informing the SC and TF and a detailed description of 
the methods is published separately. 18 (
Task Force
The TF (online supplementary appendix 1) included 77 
specialists in rheumatology, internal medicine, oral health, 
ophthalmology, gynaecology, dermatology and epidemiology, 
statisticians, general practitioners, nurses and patient repre-
sentatives from 30 countries of the five continents (Argentina, 
Australia, Brazil, Canada, China, Denmark, Egypt, Finland, 
France, Germany, Greece, Hungary, India, Israel, Italy, Japan, 
Mexico, Norway, Poland, Portugal, Slovenia, South Korea, 
Spain, Sweden, Switzerland, the Netherlands, Turkey, the UK 
and the USA). All TF members declared all potential conflicts 
of interest. After presentation of the SLR results and the SC 
proposals to the TF in the first face- to- face meeting, the TF was 
split into nine breakout working groups (see online supplemen-
tary text). Each group proposed draft language and diagnostic/
therapeutic algorithms for the respective recommendations to 
the whole TF. Safety aspects were addressed in each breakout 
group. Formal economic analyses were not performed, but cost 
aspects were considered throughout the process. Representatives 
of each breakout group reported the results of the respective 
deliberations and presented proposals for the wording of indi-
vidual recommendations to the whole TF for further discussion 
and refinement in the second face- to- face meeting.
Consensus findings
After the second meeting, a web- based Delphi procedure was 
carried out using online voting.19 The Delphi procedure was 
designed by MR- C and PB- Z, and developed, managed and 
analysed by BK using Google Forms; all clinical experts in SjS 
included in the TF were invited to participate in the Delphi 
procedure. For an overarching principle or recommendation to 
be accepted for the final document, TF members were asked to 
grade for priority according to the level of importance in the 
daily therapeutic management of SjS (from 1 as unimportant, 
no priority, no relevance to 5 as very important, a most rele-
vant point, first- order priority); a specific section allowed the 
inclusion of comments suggested to accompany individual 
items. Recommendations scoring ≥4 (‘important’) by >80% 
of participants were accepted; if this result was not achieved, 
the respective text was amended and subjected to a second elec-
tronic ballot. The approved recommendations were subjected to 
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A.Patients with SjS should be managed at, or in close collaboration with, centres of expertise following a multidisciplinary approach NA NA 90 9.2
B.The first therapeutic approach for dryness should be symptomatic relief using topical therapies NA NA 93 8.9
C.Systemic therapies may be considered for the treatment of active systemic disease NA NA 90 9.1
1.Baseline evaluation of salivary gland function is recommended before starting treatment for oral dryness 5 D 81 8.7
2.The preferred first therapeutic approach for oral dryness according to salivary gland function may be: 1a/*1b B 88 8.7
  2.1. Non- pharmacological stimulation for mild dysfunction;
  2.2. Pharmacological stimulation* for moderate dysfunction;
  2.3. Saliva substitution for severe dysfunction
3.The first- line therapeutic approach to ocular dryness includes the use of artificial tears and ocular gels/ointments 1a B 98 9.5
4.Refractory/severe ocular dryness may be managed using topical immunosuppressive- containing drops* and autologous serum eye 
drops
1a/*1b B/D 94 9.1
5.Concomitant diseases should be evaluated in patients presenting with fatigue/pain, whose severity should be scored using specific 
tools
5 D 93 9.0
6.Consider analgesics or other pain- modifying agents for musculoskeletal pain, considering the balance between potential benefits and 
side- effects
4 C 89 8.9
7.Treatment of systemic disease should be tailored to organ- specific severity using the ESSDAI definitions 4 C 89 9.0
8.Glucocorticoids should be used at the minimum dose and length of time necessary to control active systemic disease 4 C 85 9.6
9.Immunosuppressive agents should be mainly used as GC- sparing agents, with no evidence supporting the choice of one agent over 
another
4 C 82 8.9
10.B- cell targeted therapies may be considered in patients with severe, refractory systemic disease 1b B 98 8.6
11.The systemic organ- specific therapeutic approach may follow, as a general rule, the sequential (or combined) use of GCs, 
immunosuppressive agents and biologics
5 D 98 8.6
12.Treatment of B- cell lymphoma should be individualised according to the specific histological subtype and disease stage 4 C 88 9.7
LoE and GoR according to the Oxford Centre for Evidence- based Medicine—LoE (March 2009). Vote (%): % of participants scoring the recommendation as at least ‘important’ 
(score of ≥4 on 5- point scale). LoA: mean score (scale of ‘0’ as no agreement, ‘10’ full agreement).
ESSDAI, EULAR Sjögren's syndrome disease activity index; EULAR, European League Against Rheumatism; GC, glucocorticoid; GoR, grade of recommendation; LoA, levels of 
agreement; LoE, levels of evidence; NA, not applicable.
an anonymous electronic vote on the levels of agreement (LoA). 
Each recommendation was adjudicated on a scale of 0–10 (0, no 
agreement; 10, full agreement).
The draft of the manuscript was written by MR- C and PB- Z 
and was sent to TF members for comment and, after incorpo-
rating these comments, to the EULAR Executive Committee 
for review and approval. Final remarks were obtained from 
members of the TF and the Executive Committee and addressed 
in the manuscript (all modifications required approval by the 
SC), which was then submitted with the final approval of the 




As in other EULAR recommendations, the TF endorsed the 
presentation of general principles for the management of 
patients with SjS as overarching, general consensus- based recom-
mendations, since the contents were so generic that there was no 
requirement to base them on the SLR (table 1).
Patients with SjS should be managed at, or in close collaboration 
with, centres of expertise using a multidisciplinary approach(LoE na; 
LoA 9.2)
SjS may be a serious systemic disease, not only due to the heavy 
impact on the health- related quality of live (HRQoL) of the 
predominant symptoms (the triplet of dryness, fatigue and pain), 
but also due to the involvement of internal organs (systemic 
involvement) and the excess mortality caused by cancer 
(lymphoma). The low frequency of SjS in the general popula-
tion, combined with a heterogeneous glandular/systemic clinical 
expression, makes it difficult to ensure a standardised depth 
of expertise in managing the disease in non- specialised clinical 
settings. Therefore, we recommend organising SjS management 
in and around centres of expertise, including professionals 
with solid clinical experience in assessing patients with SAD. 
Assessment of SjS patients requires expert guidance, not only to 
confirm the diagnosis by ruling out non- autoimmune aetiologies 
(especially for sicca symptoms), but also to evaluate the extent of 
organs damaged and to design a specific personalised follow- up 
according to the clinical and biological patient phenotype at 
diagnosis.21 A multidisciplinary approach involving various 
health professionals is essential, with a central role for special-
ists in autoimmune diseases, who should act as the coordinator 
of diagnostic and therapeutic healthcare processes, based on a 
shared- decision policy between the patient and the specialist. 
The involvement of primary care physicians and other health 
professionals is highly recommended in the management of SjS 
patients.
The first therapeutic approach to dryness should be symptomatic 
relief using topical therapies (LoE na; LoA 8.9)
More than 95% of SjS patients present with sicca symptoms,22 
which have a significant impact on the HRQoL.23–25 Studies 
that have evaluated the natural history of glandular function 
in primary SjS (summarised by Haldorsen et al)26 report that, 
except in early stages of the disease, dysfunction may remain 
stable for long periods of time (up to 12 years) and have a 
chronic course, and no study has demonstrated that any ther-
apeutic intervention can reverse glandular dysfunction and, 
therefore, can cure sicca symptoms. Since the complete disap-
pearance of dryness, which is the desired target for all patients, 
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1.1. Interventions directly applied to the mucosal surfaces 
involved
1.2. Drugs administered orally or intravenously for systemic 
disease
1.1. Saliva substitutes, ocular tears




2.2. Active systemic disease
2.3. Severe systemic disease
2.4. Refractory systemic disease
2.5. Therapeutic response
2.1. Disease involvement that affects or has affected any of 
the organs/systems included in the clinESSDAI score
2.2. Patients with clinESSDAI score ≥1.
2.3. Patients with ESSDAI score >14, or high activity in any of 
the ESSDAI domains with a definition of high activity
2.4. Systemic manifestation/s refractory to SOC.
2.5. Decrease of ≥3 points in the global ESSDAI score
2.1. All ESSDAI domains except biological domain
2.2. Systemic activity is classified as low if ESSDAI is 1–4 (if not only due to 
biological domain), moderate between 5–13 and high ≥14.
2.3. Lymphadenopathy and lymphoma, articular, cutaneous, pulmonary, renal, 
muscular central and peripheral neurological and haematological domains.
2.4. Due to the diversity of systemic manifestations, SOC (first- line therapeutic 





3.1. Refractory ocular dryness is defined as not improvement 
after using the best- available SOC and ruling out other SjS- 
unrelated processes,
3.2. Severity should be defined after a specific 
ophthalmological evaluation of corneal damage by ocular 
scores:
3.1. SOC defined as the maximum use of artificial tears and ointments 
according to the previous recommendation
3.2. Measurement of the OSS and OSDI ocular scores
4.Recommended instruments of 
measure








4.3. ESSPRI domains, ProFAD
4.4. ESSPRI domains, BPI
4.5. ESSPRI
4.6. ESSDAI, clinESSDAI






5.5. Peripheral nerve system domain
5.6. CNS domain
5.7. Haematological domain
5.1. Diffuse vasculitis with ulcers
5.2. ILD with NHYA III/IV
5.3. Renal failure; rapidly- progressive glomerulonephritis; hypokalaemic 
paralysis
5.4. Muscular involvement with severe weakness
5.5. Neuropathy (including ganglionopathy and polyradiculopathies) with 
severe motor deficit/ataxia; cryoglobulinemic- related multineuritis
5.6. Demyelinating disease with motor deficit; cerebral vasculitis presenting 
with focal deficit; myelitis; meningoencephalitis
5.7. Severe haemolytic anaemia (<80 g/dL, <50 x109/L); severe autoimmune 
thrombocytopenia (<50 000/mm3)
BPI, brief pain inventory; CHB, congenital heart block; CIDP, chronic inflammatory demyelinating polyradiculopathy; CNS, central nervous system; ESSDAI, EULAR Sjögren's 
Syndrome Disease Activity Index; ESSPRI, EULAR Sjögren's Syndrome Patient Reported Index; EULAR, European League Against Rheumatism; G- CSF, granulocyte colony- 
stimulating factor; ILD, interstitial lung disease; KCS, keratoconjunctivitis sicca; LIP, lymphoid interstitial pneumonitis; MMF, mycophenolate mofetil; MP, methylpredisolone; MS, 
multiple sclerosis; NAC, N- acetylcysteine; NHYA, New York Heart Association; NMOSD, neuromyelitis optica spectrum disorder; NSIP, non- specific interstitial pneumonitis; OP, 
organising pneumonitis; OSDI, Ocular Surface Disease Index; OSS, Ocular Staining Score; PN, peripheral neuropathy; ROR, retinoic acid- related orphan receptor; RTX, rituximab; 
SjS, Sjögren syndrome; SOC, standard of care; STAT, signal transducer and activator of transcriptionm; SWSF, stimulated whole salivary flows; TOR, mammalian target of 
rapamycin; UIP, usual interstitial pneumonitis; UWSF, unstimulated whole salivary flows.
is at present unreachable, the TF recommends exploring the use 
of other, more realistic outcomes, such as the minimal clinically- 
important improvement or the patient- acceptable symptom 
state, following the corresponding ESSPRI definitions,13 always 
closely aligned with patient education, including coping strate-
gies. The chronic course of SjS means a daily, long- term use of 
therapies and, in this scenario, it is reasonable to recommend 
the use of therapies with a minimum of (or at least tolerable 
and reversible) side effects. This is overwhelmingly fulfilled by 
topical therapies (see definition in table 2). Various studies and 
Cochrane SLRs support the daily use of topical therapies for the 
symptomatic relief of dryness, with a significant improvement 
in HRQoL without significant side effects.7 27 28 These therapies 
should be immediately initiated after objective confirmation of 
glandular dysfunction.
Systemic therapies may be considered for the treatment of active 
systemic disease (LoE na; LoA 9.1)
Systemic disease is a key prognostic determinant of SjS and is 
linked to autoimmune- mediated organ/s dysfunction that may 
eventually become irreversible. The use of systemic immuno-
modulatory/immunosuppressive therapies (glucocorticoids 
(GCs), antimalarials, immunosuppressive agents, intravenous 
immunoglobulins and biologics) should be restricted to patients 
with active systemic disease (see definition in table 2) but only 
after a careful organ- by- organ evaluation of both severity and 
organ damage, since not all patients with active systemic disease 
will necessarily require systemic therapy (this was why the orig-
inal wording using ‘should be’ was changed to ‘may be’). As a 
general rule, the management of systemic features in SjS should 
follow a schedule consisting of a two- stage sequential regimen 
as used in other SAD, including a first intensive immunosup-
pressive approach targeted to restore organ function (induc-
tion of remission) as soon as possible, followed by a second 
therapeutic course aimed at maintaining the initial therapeutic 
response (maintenance of remission). Unfortunately, there 
are no available data in patients with SjS to support specific 
recommendations on the need for/duration of induction and 
maintenance therapies, which should therefore be decided on 
case- by- case.
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Figure 1 Algorithm of glandular function assessment and therapeutic approach in patients with primary SjS presenting with oral dryness. SjS, 
Sjögren syndrome; SWSF, stimulated whole salivary flows; UWSF, unstimulated whole salivary flows.
specific recommendations
The 12 specific recommendations form a logical sequence, 
starting with the management of the central triplet of symp-
toms (dryness, fatigue and pain) followed by the management of 
systemic, extraglandular disease (table 1).
Baseline evaluation of salivary gland function is recommended 
before starting treatment for oral dryness (LoE 5, LoA 8.7)
The therapeutic approach to oral dryness should be driven by 
the baseline measurement of salivary glandular function, and 
not by the patient’s subjective feelings, since environmental and 
personal stressing factors may influence the subjective feeling 
of dryness,29 which often does not match with the objective 
measurement of glandular function. We recommend the base-
line evaluation of salivary glandular function by measuring 
whole salivary flows before starting therapeutic interventions, 
always ruling out SjS- unrelated conditions (ie, candidiasis, 
burning mouth syndrome); salivary scintigraphy may also be 
considered.30 This item elicited significant discussions about 
the specific tests for measuring glandular function (unstimu-
lated whole salivary flows and stimulated whole salivary flows 
(SWSF), and salivary scintigraphy), especially the use of SWSF 
and salivary scintigraphy, which were considered as complicated 
tests in daily practice by several TF members, and not always 
available in all clinical settings.
The preferred first therapeutic approach for oral dryness according 
to salivary gland function may be: Non-pharmacological stimulation 
for mild dysfunction; pharmacological stimulation for moderate 
dysfunction*; saliva substitution for severe dysfunction (LoE 1a/*1b, 
LoA 8.7)
On the basis of the results obtained in the measurement of sali-
vary gland function, the therapeutic approach to oral dryness 
may be initiated based on two mechanisms: salivary gland stim-
ulation (non- pharmacological or pharmacological) or saliva 
substitution (figure 1).31
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Non-pharmacological stimulation
In patients with mild glandular dysfunction, we recommend non- 
pharmacological glandular stimulation as the preferred first- line 
therapeutic approach, using gustatory stimulants (sugar- free 
acidic candies, lozenges, xylitol) and/or mechanical stimulants 
(sugar- free chewing gum) since, in these patients, glandular func-
tion can be stimulated (figure 1). With no evidence available for 
pSjS-2002 patients, evidence was extrapolated from a Cochrane 
SLR27 focussed on the therapeutic management of oral dryness; 
the authors concluded that all non- pharmacological interven-
tions evaluated relieve subjective symptoms to some, unquanti-
fied degree, without strong evidence that any intervention was 
more effective than another, although no study evaluated the 
therapeutic response according to the degree of salivary gland 
dysfunction.27
Pharmacological stimulation
In patients with moderate glandular dysfunction, pharmaco-
logical stimulation with muscarinic agonists may be consid-
ered. Two drugs (pilocarpine and cevimeline) are licensed for 
the treatment of oral dryness, although only pilocarpine is 
licensed worldwide. The three pivotal randomised controlled 
trials (RCTs) included both primary and associated SjS patients 
fulfilling the 1993 criteria, and found significant improve-
ments in visual analogue scale (VAS) dry mouth and salivary 
flow rates, with a high frequency of adverse events.7 The 
available evidence in pSjS-2002 patients is limited to one small 
prospective study using pilocarpine that found improvement 
in subjective but not objective oral outcomes,32 and a second 
study with no detailed information about overall efficacy and 
safety.33 A third retrospective study which compares pilocar-
pine and cevimeline, only focussed on the safety profile,34 
and reported a better tolerance profile for cevimeline. The 
evidence is too limited to make a strong recommendation for 
pSjS-2002 patients (the best level of evidence should be extrap-
olated from RCTs including patients fulfilling the former 1993 
criteria). For this reason, and together with the unfavour-
able safety profile of these drugs, we recommend offering a 
trial of muscarinic agonists to patients with moderate glan-
dular dysfunction (or in those with mild dysfunction who are 
refractory or who do not wish to use non- pharmacological 
stimulation) (LoE 1b, GoR B) (figure 1). To reduce the main 
side effect (excess sweating), and based on clinical practice, 
some TF experts recommended increasing the dose progres-
sively up to 15 to 20 mg/day when possible. In patients who 
are intolerant or non- responders to muscarinic agents, some 
choleretic (anetholtrithione) or mucolytic (bromhexine, 
N- acetylcysteine) agents used as secretagogues in SjS since 
the 1980s may be considered as rescue therapies due to their 
good safety profile in the absence of alternative therapeutic 
options, and taking into account the limitations of the study 
design and the marginal benefits reported by most studies.7 
According to the SLR results, for the treatment of oral dryness 
we do not recommend the use of hydroxychloroquine (no 
placebo- differences for subjective and objective oral outcomes 
in the pivotal RCT), oral GCs, immunosuppressive agents 
(overwhelmingly- negative results with excess side effects) or 
rituximab (no placebo- differences for subjective and objective 
oral outcomes in the two pivotal RCT and one meta- analysis)
Saliva substitution
Saliva substitution should be considered the preferred ther-
apeutic approach to alleviate symptoms in patients with no 
residual glandular function (severe glandular dysfunction), in 
whom salivary glands cannot be stimulated, either by phar-
macological or non- pharmacological interventions (figure 1). 
The ideal preparation will have a neutral pH and contain 
fluoride and other electrolytes, mimicking the composition 
of natural saliva; saliva substitutes are available commer-
cially in the form of oral sprays, gels and rinses.10 Only one 
prospective study evaluated pSjS-2002 patients35 and found 
no statistically- significant placebo- differences for the primary 
outcome, although significant improvements were reported in 
some subjective oral outcomes, with no side effects reported. 
Evidence can be extrapolated from a Cochrane SLR that eval-
uated the effectiveness of topical treatments for any- cause dry 
mouth; the review found no superiority for any therapeutic 
option.27 In spite of the limited evidence available, we recom-
mend their use in the target population because, in the expe-
rience of TF members, patients often report increased oral 
comfort without significant side effects.10 Oral gel- like formu-
lations may be useful in patients with an acceptable salivary 
flow output, particularly when they complain about nocturnal 
oral dryness, although these patients often have a poor toler-
ance to saliva substitutes due to the sticky feeling caused by 
their application, which may be reduced by diluting the saliva 
substitute. Pretherapeutic evaluation of salivary function may 
also aid the choice of a specific formulation of saliva substi-
tutes (gel, saliva substitute—diluted or not,mouth rinses), with 
less thick/dense preparations being preferred for patients with 
a better- preserved glandular function.36 The preferred first- 
line use of saliva substitutes in patients with no salivary output 
elicited an intense debate within the TF, probably due to the 
apparent paradox of using a topical therapy in patients with 
severe glandular involvement. Several TF members expressed 
a dissenting view, stating that saliva substitutes should be used 
in all patients with oral dryness, irrespective of glandular func-
tion. Whether or not a saliva substitute is used, a neutral pH 
sodium fluoride gel should be prescribed to all patients with 
severe salivary dysfunction to prevent rampant caries.
The first-line therapeutic approach to ocular dryness includes 
artificial tears and ocular gels/ointments (LoE 1a, LoA 9.5)
The first line of therapy for ocular dryness should be volume 
replacement and lubrication using artificial tears (AT) and ocular 
gels, whose main ingredients are lubricants with a polymeric 
base or viscosity agent (methylcellulose, hyaluronate) with the 
aim of adding volume to the tear lake, increasing the time the AT 
remain on the ocular surface, and cushioning the ocular surface 
to reduce friction between lid and globe.37 All SjS studies testing 
AT (only one in pSjS-2002 patients) found significant improve-
ments for both subjective and objective ocular outcomes, while a 
recent Cochrane review on the use of AT for dry eye syndrome 
showed that they are safe and effective.28 We recommend that 
all SjS patients presenting with ocular dryness and/or abnormal 
ocular tests should use AT containing methylcellulose or hyal-
uronate at least twice daily, with the frequency increased to 
as often as hourly, as indicated by symptoms and/or objective 
signs. The use of preservative- free formulations of AT is mainly 
recommended in patients requiring four or more applications 
per day. Ophthalmic ointments are thicker than AT and may be 
used to provide symptom control overnight; they are typically 
used before bedtime because they produce blurred vision and 
their use should be followed by morning lid hygiene to prevent 
blepharitis.37
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Figure 2 Algorithm of glandular function assessment and therapeutic approach in patients with primary SjS presenting with ocular dryness. 
*Consider neuropathic pain if OSS≤1. **Additional criteria for severity: (1) impaired visual function (photophobia, visual acuity modification or low 
contrast sensitivity); (2) blepharospasm (secondary to ocular inflammation); (3) severe meibomian gland disease or eyelid inflammation. ***For short- 
term indications (2–4 weeks). CyA, ciclosporin A; GC, glucocorticoid; OSS, ocular staining score (Whitcher107 JP, et al. Am J Ophthalmol. 2010;149:405–
15). OSDI, ocular surface disease index (adapted from Baudouin C,108 et al. Br J Ophthalmol 2014;98:1168–1176); SjS, Sjögren syndrome.
Refractory/severe ocular dryness may be managed using topical 
immunosuppressive-containing drops* and serum eye drops (LoE 
1a/*1b, LoA 9.1)
Patients with refractory or severe ocular dryness should be 
managed by an ophthalmologist with substantial experience in 
corneal disease wherever possible. Refractory ocular dryness is 
defined as patients who do not improve after using the best- 
available standard of care (SOC) (defined as the maximum use of 
AT and ointments according to the previous recommendation) 
after ruling out other SjS- unrelated ocular processes (ie, bleph-
aritis), while severity should be defined according to the results 
obtained in a specific ophthalmological evaluation of corneal 
damage by measuring the OSS, together with patient symptoms 
as assessed by the Ocular Surface Disease Index (figure 2).
Topical NSAIDs/corticosteroids
Topical ocular non- steroidal anti- inflammatory drugs (NSAIDs) 
or corticosteroids may be prescribed by ophthalmologists as a 
short- term therapeutic approach (maximum 2–4 weeks), as 
adverse events may occur with continued use of topical NSAIDs 
(corneal–scleral melts, perforation, ulceration and severe kera-
topathy) or topical corticosteroids (infections, increased intra-
ocular pressure and worsening/development of cataracts).37 
Evidence in pSjS-2002 patients is limited to one small case- 
control study38 using topical fluorometholone which found no 
significant differences in comparison with topical ocular ciclo-
sporin A (CyA).
Topical CyA
In December 2002, an ophthalmic formulation containing 
0.05% CyA was approved by the Food and Drug Administra-
tion to treat dry eye disease in the USA based on the results of 
two RCTs including patients with keratoconjunctivitis sicca (SjS 
patients were included in variable proportions).7 There are no 
specific RCTs carried out in pSjS-2002,39 40 and only one recent 
case- control study, which reported no significant differences 
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between groups in comparison with topical fluorometholone, 
with a higher frequency of moderate- to- severe transient burning 
sensation in patients receiving CyA.38 Ophthalmologists may 
consider the use of ocular CyA drops in patients with refractory 
or severe ocular dryness requiring repeated courses of glucocor-
ticoid tear drops. The promising results of a recent small trial 
using tacrolimus tear drops41 required further confirmation in 
large trials.
Serum tear drops
In SjS patients, the role of autologous or allogenic serum has 
been tested in small uncontrolled studies showing inconsistent 
benefits (no improvement in all objective ocular outcomes eval-
uated). A recent Cochrane SLR on the use of serum tear drops 
for dry eye syndrome42 has confirmed inconsistencies in their 
possible benefits both for symptoms and objective measures, 
with no evidence of an effect after 2 weeks of treatment. Only 
one study has been carried out in pSjS-2002 patients, which 
showed significant improvement in some ocular outcomes.43 
The difficulties in preparation, the need to refrigerate the drops, 
and the potential risk of contamination should be taken into 
account.37 44 The TF recommended that serum tear drops may 
be considered in patients who are non- responders or intolerant 
to topical CyA tear drops.
Rescue therapies
Other therapeutic interventions may be considered after 
failure of the above- mentioned therapies, including topical and 
systemic therapies. A recent Cochrane SLR reviewing the use 
of plugs for dry eye syndrome45 found that the evidence was 
very limited, and concluded that improvements in subjective and 
objective ocular outcomes were inconclusive. Two studies have 
been carried out in primary-2002 SjS patients: the first found 
no significant differences between groups (insertion of plugs vs 
AT),46 and the second reported improvement in only two of four 
ocular outcomes evaluated.47 With respect to systemic therapies, 
oral muscarinic agonists may be considered on the basis of the 
improvement of subjective (not objective) ocular outcomes.7 
According to the SLR results, for the treatment of ocular dryness 
we do not recommend the use of hydroxychloroquine (no 
placebo- differences for subjective and objective ocular outcomes 
in the pivotal RCT), immunosuppressive agents (overwhelm-
ingly negative results with excess side effects) or rituximab (no 
placebo- differences for subjective and objective oral outcomes in 
the two pivotal RCT and one meta- analysis).
In summary, although patients with refractory/severe ocular 
dryness may require a more intensive ophthalmological 
follow- up and, probably, more complex therapies, including 
immunosuppressive- based tear drops (topical corticosteroids or 
CyA) and serum tear drops, the low level of current evidence for 
the use of these complex ophthalmological therapies in primary 
SjS-2002 patients do not permit the TF to establish a strong pref-
erence among the options. The expertise of the ophthalmologist 
and the specific characteristics of the patient will drive both the 
preferred first- line therapy and the sequential use of the thera-
peutic interventions.
Concomitant diseases should be evaluated in patients presenting 
with fatigue/pain, whose severity should be scored using specific 
tools (LoE 5, LoA 9.0)
Patients with primary SjS often present with general symptoms, 
of which most frequent are non- inflammatory joint/muscle pain 
and fatigue/weakness, which may have a much greater impact 
on the HRQoL than sicca features, as reported in cross- sectional 
studies.23–25 Unfortunately, these symptoms are very unspecific 
and could be related to a wide range of concomitant pathol-
ogies (osteoarthritis, hypothyroidism, hypocortisolism, vitamin 
deficiencies, depression, neoplasia) and even to some systemic 
complications of systemic SjS (arthritis, anaemia, hypokalaemia, 
osteomalacia, lymphoma, small- fibre neuropathy). A specific 
comment is needed on the association between SjS and some 
somatic functional syndromes such as chronic fatigue syndrome 
and fibromyalgia, whose peak of incidence occurs in the same 
population subset as SjS (middle- aged women).21 No studies have 
confirmed a solid aetiopathogenic autoimmune link between SjS 
and chronic fatigue syndrome/fibromyalgia48 beyond the evident 
epidemiological overlap. Since the association of these somatic 
syndromes could heavily influence both the patient and physi-
cian global health status evaluation, we recommend searching 
for these syndromes using standardised recommendations,49 
and measuring the severity of pain and fatigue using specific 
scales such as the corresponding ESSPRI domains, the Profile 
of Fatigue (for measuring fatigue) and the Brief Pain Inventory 
(for measuring pain).50 SjS patients may describe various kinds 
of pain and fatigue, and the use of both general and SjS- specific 
questionnaires will permit not only a standardised measure-
ment of their potential impact on HRQoL, but consideration 
of their influence when specific therapeutic interventions are 
initiated.10 51
Consider analgesics or other pain-modifying agents for 
musculoskeletal pain, taking into account the balance between 
potential benefits and side-effects (LoE 4, LoA 8.9)
With respect to SjS- related musculoskeletal pain, a clear prether-
apeutic differentiation must be made clinically between joint pain 
(arthralgia) and joint inflammation (arthritis, tenosynovitis).52 
The ESSDAI score classifies arthralgia in the hands, wrists, 
ankles and feet accompanied by morning stiffness (>30 min) as 
low articular activity level, always ruling out concomitant osteo-
arthritis. Arthritis is clinically diagnosed on the basis of objec-
tive inflammation of ≥1 joints (heat, redness and swelling in the 
physical examination of the affected joint) supported by ultra-
sound studies when in doubt, and the ESSDAI score classifies the 
severity of arthritis according to the number of joints involved 
(moderate <5 joints, high >5).12 The therapeutic management 
of arthritis is included in the systemic recommendations. (a) In 
patients presenting with acute musculoskeletal pain, consider 
acetaminophen or NSAIDs for symptomatic relief, always for less 
than 7–10 consecutive days at full dosage and considering the 
side effects and underlying comorbid diseases. In real life, a large 
retrospective study in 188 primary 2002 SjS patients with joint 
involvement reported that nearly one third had a rapid clinical 
response to the short- term use of analgesics/NSAIDs.53 Topical 
formulations of NSAIDs (topical diclofenac or ketoprofen) may 
be effective for local pain with fewer side effects,54 but there is no 
available evidence in SjS patients.55 (b) In patients with frequent 
episodes of acute musculoskeletal pain, the use of hydroxychlo-
roquine has been proposed based on its comparable use in other 
SAD such as systemic lupus erythematosus (SLE). Although 
uncontrolled studies have reported improvement in joint pain, 
the pivotal RCT failed to demonstrate that hydroxychloro-
quine improved pain after 24 weeks of treatment in compar-
ison with placebo, although a statistical trend was reported 
(p values between 0.06 and 0.10) at 12, 24 and 48 weeks).56 
Taking this positive trend, the lack of reported cases of retinal 
toxicity or severe adverse events, and the lack of pharmaceutical 
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alternatives with a similar indication/safety profile, the TF 
members agreed to consider the use of hydroxychloroquine in 
some patients with frequent episodes of articular pain. In real 
life, the study by Fauchais et al53 reported the use of hydroxy-
chloroquine in more than half the patients presenting with joint 
involvement. With respect to the use of biological agents to treat 
these symptoms, the data from the two pivotal RCTs57 58 on the 
effect of rituximab on pain and fatigue reported no significant 
differences in comparison with placebo for both pain and fatigue 
VAS (although some differences were found at intermediate 
evaluation points in the French study), together with no signifi-
cant placebo- differences in quality- adjusted life- year but with a 
fivefold greater economic cost,58 while a recent meta- analysis59 
confirmed no significant differences after combining the results 
of these trials. In addition, a small RCT using anakinra found no 
significant reduction in fatigue in its primary endpoint,60 while 
the promising results obtained in two small open- label studies 
(<30 patients) using epratuzumab61 or abatacept62 must be 
confirmed in further large RCTs. Therefore, we consider that the 
off- label use of biological agents to treat only musculoskeletal 
pain (even as rescue therapy) is not currently warranted. (c) In 
patients with chronic, daily non- inflammatory pain, the manage-
ment must be completely different, avoiding the repeated use of 
NSAIDs or GCs. The non- pharmacological management of pain 
should be emphasised, instead of going straight to prescribing 
medications for the symptoms. Therefore, the first therapeutic 
step should be to follow the same recommendations as those 
proposed for general chronic pain, by suggesting that physical 
activity and aerobic exercise are interventions with few adverse 
events that may reduce pain severity and improve physical func-
tion.63 In addition, a small case- control study in primary SjS 
patients showed significant improvement in aerobic capacity, 
fatigue and ratings of perceived exertion and depression in 
patients allocated to the exercise group.64 Antidepressants and 
anticonvulsants may be considered for chronic musculoskeletal 
pain, while patients with chronic neuropathic pain may require 
the use of gabapentin, pregabalin or amitriptyline (paying atten-
tion to potential exacerbations of dryness symptoms). Recent 
epidemiological data confirm that opioids must not be used.65
Treatment of systemic disease should be tailored to organ-specific 
severity using the ESSDAI definitions (LoE 4, LoA 9.0)
In non- specialised medical settings, primary SjS is often consid-
ered a chronic, non- life- threatening disease that only causes 
dryness, fatigue and pain. However, systemic involvement has 
been increasingly recognised as a key part of the disease, with 
a significant weight in dictating the prognosis and survival in 
retrospective studies.66–69 The development of the ESSDAI by 
the EULAR- SS Task Force Group has provided a helpful, objec-
tive instrument to measure systemic involvement in primary 
SjS that is accepted worldwide. According to overarching prin-
ciple C, we recommend that the use of systemic therapies (GCs, 
antimalarials, immunosuppressive agents, intravenous immu-
noglobulins, biologics) should be restricted to patients with 
active systemic disease (see definitions in table 2). However, the 
management of systemic features must be tailored to the specific 
organ involved and the severity evaluated by the ESSDAI.69 As 
an overall rule, systemic therapies may be considered for most 
patients presenting with at least moderate activity in one clinical 
domain, or with a global moderate disease activity score (score 
>5). With respect to the definition of the therapeutic response in 
systemic SjS, the TF recommends using a reduction of ≥3 points 
in the global ESSDAI score.70 It should also be considered that 
some systemic manifestations are not captured by the ESSDAI, 
including Ro- associated congenital heart block, Raynaud 
phenomenon, primary pulmonary hypertension, pleuritis, peri-
carditis, dysautonomia, interstitial cystitis and sensorineuronal 
hearing loss; these features require specific patient- by- patient 
management.
GCs should be used at the minimum dose and length of time 
necessary to control active systemic disease (LoE 4, LoA 9.6)
The frequent use of GCs in clinical practice in primary SjS 
patients69 71 72 is not supported by reliable scientific evidence, 
since no controlled study has specifically evaluated their use for 
systemic disease. Available data come mainly from retrospective 
studies (online supplementary table S2) and case series/reports, 
which also highlighted the high rate of GC- related adverse events. 
We recommend that GCs should be used at the minimum dose 
and length of time necessary to control active systemic disease, 
administering pulses of methylprednisolone followed by doses 
of 0.5 mg/kg/d or lower as induction therapy in severe presen-
tations (table 2), and doses<0.5 mg/kg/d in moderate/less- severe 
presentations, with a final target of withdrawing GCs in inactive 
patients as soon as possible or at least trying to target a main-
tenance dose of 5 mg/daily or less with the aid of GC- sparing 
immunosuppressive agents (see recommendation ‘Synthetic 
immunosuppressive agents should mainly be used as GC- sparing 
agents, with no evidence supporting the choice of one agent over 
another (LoE 4, LoA 8.9)’). No available data in SjS patients 
support specific recommendations on the rate of de- escalation 
of the GC dose, or when a GC- sparing agent should be added, 
or the length of GC therapy, although we recommend tapering 
GCs as rapidly as clinically feasible. We recommend to follow 
the EULAR evidence- based and consensus- based recommenda-
tions on the management of medium to high- dose glucocorticoid 
therapy in rheumatic diseases.73
Synthetic immunosuppressive agents should mainly be used as GC-
sparing agents, with no evidence supporting the choice of one agent 
over another (LoE 4, LoA 8.9)
Based on the potential development of chronic damage in 
patients with uncontrolled systemic disease, some patients 
may require long- term therapy with GCs, especially those 
with severe organ impairments.69 71 72 In these patients, the 
addition of immunosuppressive agents as GC- sparing agents 
is justified, always weighing the potential benefits and risks. 
The use of immunosuppressive agents in primary SjS is based 
on the same level of evidence as that of GCs, since all reported 
studies (prospective uncontrolled studies, all including less than 
50 patients) were principally centred on the efficacy in sicca 
features and laboratory parameters, but not on the efficacy in 
systemic disease, with an unacceptable rate of adverse events 
(ranging between 41% and 100%).7 The lack of head- to- head 
studies comparing the efficacy and safety profile of immunosup-
pressive agents in primary SjS-2002 (leflunomide, methotrexate, 
azathioprine, mycophenolate, cyclophosphamide) does not 
permit a recommendation on the use of one agent over another, 
except when patient characteristics or comorbidities are consid-
ered with respect to the safety profile. In addition, there is no 
information available about the dose, route of administration 
and length of treatment and we recommend a case- by- case eval-
uation following similar rules to those reported for other SAD. 
Although some TF members suggested the use of monotherapy 
with immunosuppressive agents, there was no final consensus on 
this option due to the lack of studies demonstrating the efficacy 
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Figure 3 (Continued)
of GC- free regimens in SjS, and the fact that more than 95% 
of reported cases using immunosuppressive agents in primary 
SjS-2002 received associated GCs (online supplementary table 
S2). Several immunomodulatory agents have been tested in SS, 
with marginal benefits or with an unacceptable rate of adverse 
events and are not recommended.7
B-cell targeted therapies may be considered in patients with severe, 
refractory systemic disease (LoE 1b, LoA 8.6)
The emergence of biological therapies in this century has 
increased the therapeutic armamentarium available for treating 
severe SjS. These new drugs have the highest level of evidence 
among all the drugs tested for SjS, not only because have they 
have been tested in a large number of patients (>1000), but 
also because most of reported RCTs in primary SjS have tested 
biologics. Unfortunately, their use in clinical practice is clearly 
limited by the lack of licensing. B- cell targeted therapies are 
the most frequently tested biological drugs, and include epratu-
zumab61 and belimumab,74 75 although the most widely studied 
B- cell target therapy is rituximab.57 58 76–86
Studies with available data on the efficacy of rituximab on 
systemic involvement have included more than 400 patients 
with primary SjS-2002 (online supplementary table S3), with a 
predominant use of the regimen of 2 doses of 1 g each admin-
istered 15 days apart.7 Four main systemic outcomes were 
evaluated at different follow- up times in these studies: the 
global therapeutic response, organ- specific response, change 
in the global ESSDAI score and reduction in prednisone use. 
Uncontrolled studies have reported a global response rate of 
60%–100% for systemic features, especially cryoglobulinemic 
features.76 77 79 80 86 One small RCT86 reported a significant reduc-
tion in reported extraglandular manifestations and improvement 
of musculoskeletal features at weeks 12 and 36 (p=0.029) and 
vasculitis at week 24 (p=0.03). Four studies (two retrospec-
tive, one case- control and one prospective) have reported a 
statistically- significant reduction in the global baseline ESSDAI 
score (from 9 to 20.3 to 2.5–5.2 after treatment).77–80 84 In the 
two pivotal RCTs, Devauchelle et al found no differences in the 
mean ESSDAI improvement,57 while Bowman et al58 reported 
statistically- significant placebo differences at week 36 (p=0.03) 
and a statistically- significant trend at week 48 (p=0.07) in the 
log- transformed ESSDAI score. Three retrospective studies have 
demonstrated a statistically significant reduction in the daily 
dose of GCs.76 79 80 In summary, the great majority of studies 
showed efficacy in at least one of the systemic outcomes analysed 
(global response, organ- specific response, ESSDAI reduction, 
prednisone reduction).
The results of the Efficacy and Safety of Belimumab in Subjects 
with Primary Sjögren’s Syndrome open label trial74 in 30 pSjS-
2002 patients treated with belimumab showed a reduction in the 
mean ESSDAI score from 8.7 to 5.7 at week 28 (p<0.0001), with 
a decrease of at least 4 points in 40% of cases and improvements in 
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Figure 3 (A to I) Algorithm for the therapeutic approach to patients with primary SjS presenting with organ- specific systemic involvements. NSAIDs: 
no longer than 7–10 days. HCQ: hydroxychloroquine 200 mg/day. GC (recommended dose in mg/kg/day); short- term course whenever possible; 
consider methylprednisolone pulses in severe cases. ID: immunosuppressive agents, no head- to- head comparisons. CyC: cyclophosphamide pulses 0.5 
g/15 day (maximum six pulses). Rituximab: rituximab 1 g/15 days (x2). BLM: belimumab; 10 mg/kg (0, 2 and 4 weeks and then every 4 weeks). ABA: 
abatacept 0, 2, 4 weeks and every 4 weeks. IVIg: intravenous immunoglobulins 0.4–2 g/kg 5 days. PEX: plasma exchanges. CyA, ciclosporin A; EULAR, 
European League Against Rheumatism; ESSDAI, EULAR Sjögren's syndrome disease activity index; GC, glucocorticoid; LoE, levels of evidence; NSAIDs, 
non- steroidal anti- inflammatory drugs; RA, rheumatoid arthritis; SjS, Sjögren syndrome.
parotid swelling in 77% of cases; of five patients previously refrac-
tory to rituximab, belimumab was effective in 3 (60%). In a study 
extension of the 19 patients that completed 1 year of treatment, 
a significant improvement was maintained.75 With respect to the 
safety profile, one severe adverse event was reported (pneumo-
coccal meningitis) after 6 infusions of belimumab.
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After intense discussion among the TF members and balancing 
the positive results of uncontrolled studies, the weak evidence 
reported by RCTs, and the fact that the trials were not primarily 
designed to evaluate the systemic response, we agreed that 
the use of rituximab may be considered (we changed the orig-
inal wording of ‘should be’) in patients with severe, refractory 
systemic disease, and that the best indication is probably for 
symptoms linked to cryoglobulinemic- associated vasculitis,87 
with the possible use of belimumab as rescue therapy.
The systemic organ-specific therapeutic approach may, as a 
general rule, follow the sequential (or combined) use of GCs, 
immunosuppressive agents and biologics (LoE 5, LoA 8.6)
The recommended general sequential use of the three main cate-
gories of immunosuppressive agents in SjS is based on a similar 
approach to that reported for other SAD such as SLE or vascu-
litis, with no controlled studies supporting this approach in 
SjS. As a general rule, for most systemic involvements GCs (see 
recommendation ‘GCs should be used at the minimum dose and 
length of time necessary to control active systemic disease (LoE4, 
LoA9.6)’) may be considered the first- line option in patients 
with active systemic disease, and immunosuppressive agents and 
biologics as second/third line options to be used in patients intol-
erant or refractory to GCs, those with severe disease or those in 
whom long- term GC use is anticipated. In spite of the greater 
amount of scientific evidence data available for rituximab in 
comparison with GCs and immunosuppressive agents, the lack of 
licensing, the lack of controlled studies for systemic disease and 
the lack of head- to- head comparisons between rituximab and 
classic immunosuppressants (especially with respect to the safety 
profile) were issues to be considered. After an intense discussion 
among the TF members, the TF agreed to merge the two options 
as second- line therapies (adding a specific note about the use of 
rituximab as especially recommended for associated cryoglobu-
linemic vasculitis), always with a careful case- by- case assessment 
of the use of rituximab in an off- label context, evaluating poten-
tial benefits and adverse effects patient- by- patient (table 2), and 
taking into account the fact that their use will depend on drug 
availability and national regulations.
Unfortunately, after analysing the available evidence, no 
controlled data was identified to support a differentiated organ- 
guided therapeutic approach for systemic SjS, and some TF 
members recommend no strictly adherence to sequential therapy 
management, with an individualised therapeutic approach being 
preferable. However, on the basis of the results, principally from 
retrospective studies (online supplementary table S2), together 
with the clinical experience of the TF members, a list of consensus- 
based algorithms defining SOC and second/third line therapies was 
proposed for each clinical ESSDAI domain (figure 3A–I); Ro- asso-
ciated congenital heart block (not included in the ESSDAI) was also 
included due to its prognostic significance. There was no consensus 
on the proposal to make recommendations for organ- specific 
maintenance therapeutic regimens.
Treatment of B-cell lymphoma should be individualised according to 
the specific histological subtype and disease stage (LoE 4, LoA 9.7)
Among the systemic manifestations of SjS, lymphoma is one 
of the worst complications, with standardised incidence ratios 
for B- cell lymphoma ranging between 7 and 9 in population- 
based studies and between 16 and 48 in hospital- based studies.88 
Although the vast majority of cells infiltrating the salivary glands 
of patients with primary SjS are T cells, the majority of lymphomas 
reported are of B- cell origin with a ratio between B and T- cell 
lymphomas of 15:1; three subtypes of B- cell lymphoma account 
for more than 90% of reported cases in primary SjS: mucosa- 
associated lymphoid tissue (MALT) lymphoma, other marginal 
zone lymphomas (MZL) and Diffuse large B cell lymphoma.88 
Following the diagnosis of lymphoma, therapy should be indi-
vidualised according to the specific histological subtype defined 
according to the WHO 2016 classification89 and the corre-
sponding current therapeutic guidelines, with a personalised 
therapeutic approach driven by the haematologist/oncologist. 
For primary SjS-2002 patients diagnosed with low grade haema-
tological neoplasia, some clinicians recommend a watchful 
waiting approach when lymphoma only affects the exocrine 
glands,90 especially in the absence of constitutional symptoms, 
systemic features or B- cell activation biomarkers.3 The decision 
to treat low- grade lymphomas or not must be discussed in a 
multidisciplinary committee, taking into account the fact that 
they are linked to the disease activity and are the ultimate stage 
of autoimmune B- cell activation. Moreover, low grade B- cell 
lymphomas have a potential risk of progression to more aggres-
sive types of lymphoma.3 In patients with disseminated MALT 
lymphoma or with concomitant high disease activity, chemo-
therapy may be considered on a case- by- case basis.3 For patients 
with marginal zone lymphomas, small lymphocytic lymphoma 
(SLL) and lymphoplasmacytic lymphoma (LPL) in early disease 
stages (in particular, stage I or non- bulky stage II), treatment 
may include radiotherapy (with or without chemotherapy), 
although a watch- and- wait strategy could be an alternative to 
spare the side effects of therapy.91 For patients with moderate/
high grade haematological neoplasia, treatment is based on stan-
dard rituximab- based chemotherapy regimens. The benefit of 
adding rituximab to chemotherapy has been demonstrated in 
a meta- analysis in patients with follicular lymphomas, mantle 
cell lymphomas and other indolent lymphomas.91 Rituximab 
plus fludarabine or bendamustine (BR) are the recommended 
first- line therapy for MZL, SLL and LPL; a recent study in 13 
patients with pSjS-2002 (77% stage IV) complicated by MZL has 
reported the efficacy of the BR combination in all 13 cases, with 
improvement in the other SjS non- lymphomatous manifestations 
and with a good safety profile.92
dIsCussIon
The EULAR recommendations for the management of SjS with 
topical and systemic therapies management have been devel-
oped by a large, multidisciplinary, multiprofessional team. In 
summary, nine RCTs (only three including 120–130 patients), 
18 prospective (all including between 10 and 50 patients) and 
five case- control studies were selected to support the scientific 
evidence presented here. This is a small number of studies that 
is not comparable with rheumatoid arthritis (RA) or with other, 
more closely- related diseases, such as SLE or systemic vasculitis. 
Therefore, the evidence accumulated in this century reveals SjS 
as a true orphan disease from a therapeutic point of view,59 93 
with the absence of any efficacious agent, a situation that is in 
clear contrast with the significant advances achieved in both 
basic and clinical research during this period. As a consequence 
of the limited evidence available, therapeutic decisions in daily 
practice are often based on a mix of reported expert opinions 
and personal experience, which may vary widely between coun-
tries: therefore, the present recommendations are based on the 
input of experts from 16 European countries and wide interna-
tional representation from the other continents. In addition, SjS 
presents with a wide range of signs and symptoms (not only the 
key features of dryness, fatigue and pain, but also those derived 
from organ- specific systemic involvements and lymphoma), with 
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a large number of different specialties involved and, therefore, 
with a wide variety of potential interventions. Methodologically, 
we have also taken into account the continuous changes in clas-
sification criteria since 1986 and, in consequence, the contin-
uous changes in the target population classified as primary SjS. 
For this reason, we decided, in the Population, Intervention, 
Comparison, Outcomes and Study design strategy, to focus on 
the evidence collected from therapeutic studies including pSjS-
2002 patients, since these criteria have been used for a longer 
and more- recent period and because of their similarity with the 
recent 2016 American College of Rheumatology (ACR)/EULAR 
criteria.16
In SjS, we are very far from the ‘disease modification’ concept 
as the mainstay of treatment (as used in other diseases such as 
RA, a concept that allows the use of the term disease modifying 
antirheumatic drugs for many drugs that have demonstrated 
the ability to prevent structural damage progression in RA). A 
rapid overview of the LoE that support each statement (table 1) 
shows that all recommendations for managing oral and ocular 
dryness are principally supported by evidence extrapolated from 
Cochrane SLRs that evaluated their management in mixed aeti-
ological populations; on the management/prevention of dryness- 
related complications (oral ulcers, candidiasis, caries/dental 
complications, ocular infections), the management of dryness 
other than oral or ocular, or the role of non- therapeutic inter-
ventions in dryness, there was a very limited number of studies 
carried out in 2002 primary SjS patients, and we recommend 
following published guidelines.9–11 37 94 With respect to the most 
frequently used synthetic drugs (GCs and immunosuppressive 
agents), the available evidence came from isolated uncontrolled 
studies. The only exceptions were for hydroxychloroquine 
and rituximab, which were both tested in well- designed RCTs, 
although there were no statistically- significant differences with 
respect to placebo for the primary outcome (efficacy in dryness, 
fatigue and pain). With respect to systemic disease, the use of 
rituximab was supported by a large number of studies, mainly 
uncontrolled. We are also very far from defining specific treat-
ment targets (especially searching for remission in non- systemic 
features), but it may be useful to use the EULAR disease activity 
states,70 considering that any higher disease activity has to be 
regarded as inadequate disease control, thus mandating a ther-
apeutic intervention, or that low disease activity achieved after 
therapy may be potentially acceptable for some organs. In any 
case, as stated in previous EULAR recommendations,95 commu-
nication with the patient to clarify and agree on the treatment 
goal and the means to attain it is of utmost importance. Moni-
toring should be frequent in patients with systemic active disease, 
although the frequencies of follow- up examinations should 
be adjusted in accordance with the individual disease activity 
state,70 namely, more frequently, such as monthly, when patients 
have high disease activity, and less frequently, such as every 6–12 
months, when patients have low disease activity.
Lessons should be learnt from the first biological tested in 
primary SjS (infliximab). The excellent results of tumour necrosis 
factor- targeted therapies in RA led to their testing in patients 
with primary SjS, in spite of the large pathological and clinical 
differences between the two diseases. After the report of prom-
ising results in small open- label studies (one of which has been 
recently retracted by the authors), the first well- designed RCT 
showed no differences between the infliximab and placebo arms 
for the primary outcome. The same disappointing results have 
been obtained for other drugs reported as efficacious according 
to uncontrolled data (hydroxychloroquine and rituximab) 
without significant results for the primary outcomes when tested 
in RCTs. In SjS trials, two common issues may help to explain 
the negative results. The first is the choice of primary end- points. 
Most studies used composite primary outcomes based mainly on 
the subjective evaluation of dryness, fatigue, pain96 ; the strong 
influence of personal and environmental factors on the intensity 
of this triad of symptoms could explain the lack of significant 
differences (a higher rate of placebo- related response), together 
with inadequate patient selection (too low degree of disease 
activity), the influence of concomitant drugs and the hetero-
geneity of diagnostic tests. The composite ESSDAI to measure 
systemic activity was used in the most recent RCT as a secondary 
end- point and frequently calculated retrospectively (although 
one of the weaknesses of this outcome could be the difficulty 
in differentiating activity due to chronic damage in different 
domains). The preliminary results of two new RCTs where 
ESSDAI was the primary end- point demonstrated efficacy of the 
active drug versus placebo (anti- CD40 and the combination of 
leflunomide and hydroxychloroquine).97 98 The second issue is 
the limited number of patients randomised (no more than 50–60 
patients per arm), taking into account the clinical and immuno-
logical heterogeneity of SjS as an SAD (such as SLE or systemic 
vasculitis); in SLE, the pivotal trials that allowed the licensing of 
belimumab were obtained from two trials including nearly 1000 
patients each. Some promising results recently reported in small 
open- label studies testing biologics (belimumab, anakinra) must 
be confirmed in further large well- designed RCTs, while advance 
results of a large trial in primary SjS do not indicate a clinical 
benefit of abatacept.99 The current therapeutic pipeline in SjS, 
as shown by the  clinicaltrials. gov webpage, is that the biologic 
therapeutic approach overwhelmingly used in SjS until now 
(targeting B- cell depletion) is shifting towards the evaluation of 
biologics targeting cytokines, T- cells and intracellular signalling 
pathways.100 With respect to ongoing trials, considerable interest 
is centred on the B cell survival factor (BAFF) pathway, inves-
tigating the effect of monoclonal antibodies targeting BAFF- 
receptor or the association between B- cell depletion and BAFF 
inhibition. In addition, studies are testing inhibition of other 
pathways activating B cells. Lastly, four ongoing trials are testing 
other pathways or the use of other cytokine- based therapies 
including tocilizumab, abatacept, filgotinib (a janus kinase inhib-
itor) and human recombinant Il-2.
Therapeutic research in SjS should probably be reconsidered 
in order to explore new pathogenic targets outside the glandular 
tissue (ie, neuroendocrine pathways), and to search for a more 
personalised therapeutic approach based on genetic, clinical, 
immunological and/or histopathological characteristics. It is not 
improbable that future RCTs would benefit from more selected 
patient cohorts, possibly including newly diagnosed SjS patients, 
the findings of early salivary gland ultrasound changes,101–103 
or evidence of early high disease activity at diagnosis22 before 
permanent damage has been established and the changes are 
still reversible. Patients with sicca- limited disease differ from 
those with systemic disease, as do immune- negative patients 
from those carrying Ro autoantibodies or cryoglobulins, while 
recent etiopathogenic studies are beginning to divide SjS patients 
according to the genetic profile between those with or without a 
predominant IFN- I gene expression signature.104–106 Sensitivity 
analyses searching for a differentiated response to therapies in 
these subsets of patients (sicca- limited vs systemic; Ro+ vs Ro-; 
positive vs negative salivary gland biopsy; positive vs negative 
IFN- I signature) might help to better delineate the therapeutic 
effect of a drug tested in primary SjS, although this would require 
a greater number of patients randomised than those included in 
reported trials.
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box 1 Research agenda
 ► Is there a specific, differentiated treatment of lymphomas 
related to SjS?
 ► Is combination therapy a potential intervention to explore in 
SjS?
 ► Exploring targeted therapies against Th17 cytokines, IFNα, 
RORɣt expression, Janus kinases (JAKS), STATs and mTOR 
intracellular pathways or interleukin-1.
 ► Searching for predictive factors of biological response.
 ► Potential use of sequential or intralesional use of biological 
therapies.
 ► Encouraging the development of new and innovative 
therapies.
 ► In what proportion of systemic patients is induction therapy 
with current therapeutic options effective in inducing 
sustained remission?
 ► Is the use of immunosuppressive and biologic agents safe 
and efficacious in the absence of concomitant glucocorticoid 
treatment?
 ► How safe and efficacious is the off- label use of other 
biologics after rituximab has failed?
 ► Can we find predictors of differential response to the 
synthetic and biological drugs used in SjS?
 ► Can we predict who will maintain remission after withdrawal 
of glucocorticoids?
 ► Will we be able to develop precision (personalised, 
stratified) medicine approaches in SjS? (IFN signature +/-; 
immunological or histopathological markers +/-)?
 ► Which biomarkers will help identify better predictors of poor 
outcomes?
In conclusion, the 2019 EULAR recommendations are based 
on the recent evidence collected on the management of primary 
SjS patients and on discussions by a large, broadly- based inter-
national TF. The recommendations synthesise current thinking 
on SjS treatment in a set of overarching principles and recom-
mendations. These have been informed by a specific SLR on 
the efficacy and safety of topical and systemic interventions, 
although the high- quality scientific evidence focused on primary 
SjS patients fulfilling the currently- accepted sets of criteria was 
limited. However, the TF is convinced that adhering to these 
recommendations, including shared decision- making, assessing 
disease activity regularly with the ESSDAI instrument, and 
applying the sequence of drugs as proposed, will improve 
overall outcomes in a clear majority of patients with SjS. New 
research information on treatment strategies, predictive markers 
and other aspects will soon become available and will probably 
require an update of the recommendations in coming years (see 
Future Agenda box 1). Until then, we hope that the current 
recommendations will be broadly applied in clinical practice 
and/or serve as a template for national societies to develop local 
recommendations.
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